Search - tctmd.com

Displaying 21 - 40 of 73

Sort: Relevancy | Date

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Caitlin E. Cox

February 07, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News ISET 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

Caitlin E. Cox

February 08, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

Advertisement

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Veryan Medical receives PMA approval for BioMimics 3D

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content